23
Participants
Start Date
March 31, 2021
Primary Completion Date
November 30, 2023
Study Completion Date
January 10, 2024
Turoctocog alfa pegol
Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Kurume University Hospital, Pediatrics, Fukuoka
Gifu University Hospital, Gifu
Saitama Medical University Hospital, Pediatrics, Iruma-gun, Saitama
University Hospital Kyoto Prefectual University of Medicine, Kamigyo-ku, Kyoto
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa
St. Marianna University School of Medicine Hospital, Kanagawa
Nara Medical University Hospital_Pediatrics, Nara
Nanbu Medical Center & Children's Medical Center, Okinawa
Shibuya Children's Clinic, Department of Pediatric, Saitama
Lake Children Clinic, Shiga
Shizuoka Children's Hospital, Hematology-Oncology, Shizuoka
Shizuoka Children's Hospital, Shizuoka
Nippon Medical School Hospital, Tokyo
Tokyo Medical Univ. Hospital_Laboratory Medicine, Tokyo
Tokyo Medical Univ. Hospital, Tokyo
Ogikubo Hospital_Tokyo, Tokyo
Nihonkai Sogo Hospital_Internal Medicine, Yamagata
Nihonkai Sogo Hospital, Yamagata
St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,, Yokohama-shi, Kanagawa
Lead Sponsor
Novo Nordisk A/S
INDUSTRY